All In Biotech

Free tool

FAERS Monitor: Elucirem

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216986 or its brand name (Elucirem, Gadopiclenol). Reports on generic versions are filed under their own applications.

Reports

278

Serious

100

36% of reports

Hospitalization

30

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urticaria64
  • pruritus45
  • nausea42
  • vomiting38
  • rash28
  • erythema20
  • anaphylactic reaction17
  • dyspnoea17
  • hypersensitivity16
  • dizziness15
  • headache12
  • paraesthesia11
  • contrast media reaction10
  • feeling hot9
  • sneezing9

Reports by year received

View as table
YearReports
202312
202447
2025121
202698

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,881 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contrast media reactionSignal10322.0175.02,875
sneezingSignal930.416.0227
urticariaSignal6428.923.31,710
anaphylactic reactionSignal1723.314.7341
feeling hotSignal911.15.873
pruritusSignal458.96.8312
erythemaSignal207.44.8105
hypersensitivitySignal166.54.170
vomitingSignal386.14.6161
paraesthesiaSignal115.33.034
rashSignal284.93.484
nauseaSignal424.03.096
dizzinessSignal152.31.410
dyspnoeaSignal172.31.411
headache121.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.